Glioblastoma (GBM) is the most common malignant brain tumor in adults with a median survival of 14.6 months. A contributing factor to GBM aggressiveness is the intratumoral expression of the potently immunosuppressive enzyme, indoleamine 2,3 dioxygenase 1 (IDO1). The enzymatic activity of IDO1 is associated with the conversion of tryptophan into downstream kynurenine (Kyn), which has previously been hypothesized to contribute toward the suppression of tumor immunity. Utilizing the syngeneic, immunocompetent, intracranial GL261 cell GBM model, we previously demonstrated that tumor cell, but not non-tumor cell IDO1, suppresses T cell-mediated brain tumor regression in mice. Paradoxically, we also showed that the survival advantage mediated by immune checkpoint blockade is abrogated by non-tumor cell IDO1 deficiency. Here, we have built on our past observations and confirm the maladaptive role of tumor cell IDO1 in a novel mouse GBM model. We also demonstrate that, non-tumor cells, rather than mouse GBM cells, are the dominant contributor to IDO1-mediated enzyme activity. Finally, we show the novel associations between maximally-effective immune-checkpoint blockade-mediated survival, non-tumor cell IDO1 and intra-GBM Kyn levels. These data suggest for the first time that, GBM cell-mediated immunosuppression is IDO1 enzyme independent, while the survival benefits of immune checkpoint blockade require non-tumor cell IDO1 enzyme activity. Given that current clinical inhibitors vary in their mechanism of action, in terms of targeting IDO1 enzyme activity versus enzyme-independent effects, this work suggests that choosing an appropriate IDO1 pharmacologic will maximize the effectiveness of future immune checkpoint blockade approaches.
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Introduction
Glioblastoma (GBM) is a primary malignant brain cancer in adults with a median overall survival of 14.6 months (Stupp et al., 2005) . Patients diagnosed with GBM typically undergo conventional therapy including surgical resection of the tumor, when possible, followed by irradiation and chemotherapy. Even with these aggressive treatments, the overall prognosis remains grim; highlighting the need for more effective and less toxic approaches. To address this clinical necessity, immunotherapy has been proposed as a potential beneficial strategy for GBM patients (Reardon et al., 2015; Binder et al., 2015) , based on the recent demonstration of improved survival in terminal cancer patients that are otherwise refractory to treatment (Wolchok et al., 2013; Larkin et al., 2015) . However, applying immunotherapy to GBM is challenging given the unique immunologic specialization of the central nervous system (CNS) that includes: anatomical barriers limiting lymphatic drainage, low MHC expression levels by parenchymal glial cells and immunosuppressive gene expression that increases with age (Ladomersky et al., 2016) .
Indoleamine 2,3-dioxygense 1 (IDO1) is an interferon-inducible mediator and rate-limiting enzyme associated with the conversion of tryptophan (Trp) into kynurenine (Kyn). This pathway is wellestablished to play an important role in driving cancer-induced immunosuppression and is a high-profile therapeutic target (Munn et al., 2012; Zhai et al., 2015b; Uyttenhove et al., 2003) . In
